Helicon Group (ASX: HCG) has received notices of acceptance from the Australian Patents Office of two patent applications in relation to the company's BreatheAssist™ product.
BreatheAssist™ is a new multi-functional nasal dilation technology.
The Australian patent acceptance follows the prior granting of patents in Japan, China and New Zealand, and corresponding patents in the U.S. with patents pending in Europe.
The acceptances were advertised in the Supplement to the Australian Official Journal of Patents on 15 September 2011.
Fabio Pannuti, chief executive officer for Helicon commented, “The acceptances of these two further patent applications are important achievements in the protection of the intellectual property in our BreatheAssist™ product and we look forward to the issuance of the Deeds of Letters Patent Certificates shortly.
“The acceptances follow the recent announcement of our exciting clinical trial data which demonstrates very clear efficacy of BreatheAssist™ in enhancing airflow through the nostrils."
Helicon said that the latest patents provided the company with even greater confidence about the commercial potential for BreatheAssist™.
Originally published at: http://www.proactiveinvestors.com.au/companies/news/19721/helicon-group-receives-breatheassist-patent-from-australian-patents-office-19721.html
Proactiveinvestors is a leading multi-media news organisation, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt and London.
No comments:
Post a Comment